Core Viewpoint - The collaboration between Chongqing Yaoyou Pharmaceutical Co., Ltd. and Pfizer, involving a licensing agreement for the oral GLP-1 receptor agonist YP05002, signifies a strategic move in the pharmaceutical industry, highlighting the potential for significant financial returns and global market expansion [1][2]. Group 1: Licensing Agreement Details - Chongqing Yaoyou Pharmaceutical has signed a collaboration and license agreement with Shanghai Fosun Pharmaceutical and Pfizer, granting Pfizer exclusive rights to develop, use, produce, and commercialize the GLP-1 receptor agonist YP05002 globally [1]. - Pfizer will pay up to $500 million in non-refundable upfront and milestone payments, including an upfront payment of $150 million and up to $350 million based on clinical trial and commercialization progress in key markets [1]. Group 2: Financial Implications - Based on the annual net sales of the licensed product, Pfizer is obligated to pay up to $1.585 billion in sales milestone payments to Yaoyou Pharmaceutical [2]. - Royalties will be paid by Pfizer to Yaoyou Pharmaceutical based on the annual net sales of the licensed product, at an agreed percentage of up to two digits [2]. Group 3: Product and Market Potential - YP05002 is an orally administered GLP-1 receptor agonist developed by Yaoyou Pharmaceutical, aimed at treating type 2 diabetes, obesity, and related metabolic disorders [2]. - The potential indications for YP05002 include long-term weight management, type 2 diabetes, and non-alcoholic fatty liver disease, with the product currently in Phase I clinical trials in Australia as of December 9, 2025 [2]. - The licensing agreement reflects recognition of Yaoyou Pharmaceutical's innovative research and development capabilities, which may accelerate the clinical development and commercialization of the product globally, benefiting more patients [2].

格隆汇12月10日丨重药控股(000950.SZ)公布，公司参股子公司药友制药与上海复星医药产业发展有限 公司及辉瑞共同签订《Collaboration and License Agreement》（简称"许可协议"），（其中主要包括） 由药友制药就口服小分子胰高血糖素样肽-1 受体（GLP-1R）激动剂（包括 YP05002）及含有该活性成 分的产品授予辉瑞于许可区域（即全球范围）及领域（人类、动物所有适应症的治疗、诊断及预防）独 家开发、使用、生产及商业化权利；就本次许可，药友制药将有权依约获得（其中包括）不可退还的首 付款 15,000 万美元及基于许可产品临床、商业化进展获得开发里程碑付款至多 35,000 万美元。 责任编辑：山上 YP05002为药友制药自主研发并拥有自主知识产权的口服小分子胰高血糖素样肽-1受体（GLP-1R)激动 剂；其主要通过激活人的GLP-1R，促进胰腺的胰岛素分泌和降低胰高血糖素分泌，在胃肠道抑制胃排 空和肠道的蠕动，并通过影响中枢抑制食欲减少能量的摄入等机制，用于治疗2型糖尿病、肥胖症及其 相关疾病。YP05002拟用于代谢领域相关疾病的治疗，潜在适应症包括但不限于长期 ...

Core Viewpoint - Chongqing Pharmaceutical (Group) Co., Ltd., a subsidiary of Zhongyao Holdings, has granted Pfizer exclusive rights to develop, use, produce, and commercialize the oral small molecule GLP-1 receptor agonist YP05002 and related products globally for human and animal indications [1] Group 1 - Zhongyao Holdings holds a 38.67% stake in Yaoyou Pharmaceutical, which is involved in the licensing agreement with Pfizer [1] - The agreement includes an upfront non-refundable payment of $150 million and potential milestone payments of up to $350 million based on clinical and commercialization progress [1] - YP05002 is developed by Yaoyou Pharmaceutical and is designed to treat type 2 diabetes, obesity, and related diseases through various mechanisms, including insulin secretion enhancement and appetite suppression [1] Group 2 - The potential indications for YP05002 include long-term weight management, type 2 diabetes, and metabolic dysfunction-related fatty liver disease [1]

Core Viewpoint - Chongqing Pharmaceutical (Group) Co., Ltd., a subsidiary of Zhongyao Holdings, has granted Pfizer exclusive rights to develop, use, produce, and commercialize the oral small molecule GLP-1 receptor agonist YP05002 and related products globally for various indications [1] Group 1 - Zhongyao Holdings holds a 38.67% stake in Yaoyou Pharmaceutical, which is the company developing YP05002 [1] - Yaoyou Pharmaceutical will receive a non-refundable upfront payment of $150 million and up to $350 million in milestone payments based on clinical and commercialization progress of the licensed product [1] - YP05002 is designed to treat type 2 diabetes, obesity, and related diseases by activating GLP-1 receptors to enhance insulin secretion and reduce glucagon secretion, among other mechanisms [1] Group 2 - Potential indications for YP05002 include long-term weight management, type 2 diabetes, and metabolic dysfunction-related fatty liver disease [1]

人民财讯12月10日电，重药控股（000950）12月10日公告，公司下属控股子公司重庆医药(集团)股份有 限公司持有重庆药友制药有限责任公司(简称"药友制药")38.67%股权。12月9日，药友制药与上海复星 医药（600196）产业发展有限公司及辉瑞共同签订许可协议，药友制药就口服小分子胰高血糖素样肽-1 受体(GLP-1R)激动剂(包括YP05002)及含有该活性成分的产品(以下简称"许可产品")授予辉瑞于许可区 域(即全球范围)及领域(即人类、动物所有适应症的治疗、诊断及预防)独家开发、使用、生产及商业化 权利；就本次许可，药友制药将有权依约获得(其中包括)不可退还的首付款15000万美元及基于许可产 品临床、商业化进展获得开发里程碑付款至多35000万美元。 ...

Core Viewpoint - Chongqing Yaoyou Pharmaceutical, a subsidiary of Zhongyao Holdings, has signed a Collaboration and License Agreement with Pfizer, granting exclusive global rights for the development, use, production, and commercialization of the GLP-1R agonist YP05002 and related products [1] Group 1 - The agreement includes an upfront payment of $150 million, potential development milestone payments of up to $350 million, and sales milestone payments of up to $1.585 billion, along with royalties based on agreed percentages [1] - As of the announcement date, YP05002 is in Phase I clinical trials in Australia [1]

重药控股公告，公司控股子公司重药股份以2.65亿元公开挂牌方式转让持有的化医财务公司20%股权， 受让方为重庆建峰工业集团有限公司。2025年12月9日，化医财务公司取得重庆市市场监督管理局换发 的营业执照，本次股权工商变更登记手续已办理完成。转让完成后，重药股份不再持有化医财务公司股 权。 ...

证券代码：000950 证券简称：重药控股 公告编号：2025-087 重药控股股份有限公司 关于参股子公司签订许可协议的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.协议类型：独家开发、使用、生产及商业化许可 2.协议主要内容：公司下属控股子公司重庆医药（集团）股份有限公司持有 重庆药友制药有限责任公司（以下简称"药友制药"）38.67%股权，药友制药就口 服小分子胰高血糖素样肽-1 受体（GLP-1R）激动剂（包括 YP05002）及含有该 活性成分的产品（以下简称"许可产品"）授予辉瑞于许可区域（即全球范围）及 领域（即人类、动物所有适应症的治疗、诊断及预防）独家开发、使用、生产及 商业化权利；就本次许可，药友制药将有权依约获得（其中包括）不可退还的首 付款 15,000 万美元及基于许可产品临床、商业化进展获得开发里程碑付款至多 35,000 万美元。 3.特别风险提示 根据国内外研发经验，药品研发是项长期工作，需要经过临床试验、注册等 诸多环节，具有不确定性。于本次许可中所约定的开发里程碑款项、销售里程碑 款项及特许权使用 ...

证券代码：000950 证券简称：重药控股 公告编号：2025-088 2025 年 10 月 28 日，重药控股股份有限公司（以下简称"公司"）披露了《关 于挂牌转让重庆化医控股集团财务有限公司 20%股权暨关联交易的公告》（公告 编号：2025-079），公司控股子公司重庆医药（集团）股份有限公司（以下简称 "重药股份"）以公开挂牌方式转让持有的重庆化医控股集团财务有限公司（以下 简称"化医财务公司"）20%股权，摘牌方即受让方为重庆建峰工业集团有限公司， 转让价格 26,477.11 万元。转让完成后，重药股份不再持有化医财务公司股权。 一、进展情况概述 2025 年 12 月 9 日，化医财务公司取得了重庆市市场监督管理局换发的营业 执照，本次转让化医财务公司 20%股权的工商变更登记手续已办理完成。 二、对公司的影响 本次变更完成后，重药股份不再持有化医财务公司股权。 重药控股股份有限公司 关于挂牌转让重庆化医控股集团财务有限公司 20%股权暨关联交易完成工商变更的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 特此公告。 重药控股股份有限公司 ...

以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。 从资金流向上来看，当日医药商业板块主力资金净流出1.74亿元，游资资金净流出1.05亿元，散户资金 净流入2.79亿元。医药商业板块个股资金流向见下表： 证券之星消息，12月10日医药商业板块较上一交易日上涨0.71%，重药控股领涨。当日上证指数报收于 3900.5，下跌0.23%。深证成指报收于13316.42，上涨0.29%。医药商业板块个股涨跌见下表： ...